top of page
  • Active, not recruiting

NCT00378105: Phase 1/2: Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in NDMM

Updated: Sep 27, 2022

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma

VRd

The purpose of this study is to determine the safety and efficacy of the bortezomib, lenalidomide and dexamethasone combination in patients with newly diagnosed multiple myeloma. We are looking for the highest dose of the combination that can be given safely and see how well it works as a combination in newly diagnosed patients.


Sponsor:

Dana-Farber Cancer Institute


Collaborators:

Brigham and Women's Hospital

Beth Israel Deaconess Medical Center

Massachusetts General Hospital

Celgene Corporation

Millennium Pharmaceuticals, Inc.

 

ClinicalTrials.gov Identifier: NCT00378105

Official Title: An Open-Label Phase I/II Study of the Safety and Efficacy of Bortezomib, Lenalidomide and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

First Posted : September 19, 2006

https://clinicaltrials.gov/ct2/show/NCT00378105

 

Drug: Bortezomib

Drug: Lenalidomide

Drug: dexamethasone

 

Locations

Massachusetts General Hospital

Beth Israel Deaconess Medical Center

Dana-Farber Cancer Institute

 

Blood; 2010

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

https://pubmed.ncbi.nlm.nih.gov/20385792/







Posts Archive
bottom of page